الفهرس 
Indications for Diabetic VitrectomyOnly 14 pages are availabe for public view
 |  | from | 166 |  |  |
| | | from | 166 | | |
Abstract
Vitrectomy in diabetic retinopathy is indicated for many purposes
including tractional retinal detachment involving or threatening the
macula, combined tractional/rhegmatogenous retinal detachment,
fibrovascular tissue covering and distorting the macula and persistent
vitreous hemorrhage. One of the major complications of diabetic
vitrectomy is intraoperative and postoperative vitreous hemorrhage.
Bevacizumab is used as an adjunct to diabetic vitrectomy to reduce the
incidence of this complication through inducing regression of
neovascularization. It is injected preoperatively then pars plana
vitrectomy is done.
Patients and methods: In this study, bevacizumab was injected
intravitreally in 20 eyes with proliferative diabetic retinopathy
complicated with tractional retinal detachment involving or threatening
the macula, combined tractional/rhegmatogenous retinal detachment and
fibrovascular tissue covering and distorting the macula. Fundus colored
photography and fluorescein angiography were performed before and
after the injection. Vitrectomy was then accomplished for all the eyes and
the eyes were followed up for 3 months.
Results: Regression of neovessels of the disc and elsewhere of the
retina led to significant reduction of intra- and postoperative bleeding.
Significant gain in best corrected visual acuity was noticed 2 to 3 months
postoperatively.
Conclusion: Bevacizumab is effective as an adjunct to vitrectomy
in diabetic retinopathy reducing the severity of intraoperative and the
incidence of postoperative bleeding.
Key words: Bevacizumab, intraoperative and postoperative
vitreous hemorrhage, proliferative diabetic retinopathy, vitrectomy.